直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 113620
タイトル別表記
Association Between SLFN11 and Antitumor Activity of Trabectedin
著者
Iwasaki, Junya Taiho Pharmaceutical|Tokushima University
Komori, Toshiharu Taiho Pharmaceutical
Nakagawa, Fumio Taiho Pharmaceutical
Nagase, Hideki Taiho Pharmaceutical
Uchida, Junji Taiho Pharmaceutical
Matsuo, Kenichi Taiho Pharmaceutical
キーワード
DNA repair
anticancer drug
sarcoma
Schlafen11
trabectedin
資料タイプ
学術雑誌論文
抄録
Background/Aim: Trabectedin is a DNA-damaging agent and has been approved for the treatment of patients with advanced soft tissue sarcoma. Schlafen 11 (SLFN11) was identified as a dominant determinant of the response to DNA-damaging agents. The aim of the study was to clarify the association between SLFN11 expression and the antitumor activity of trabectedin. Materials and Methods: The antitumor activity of trabectedin was evaluated under different expression levels of SLFN11 regulated by RNA interference and CRISPR-Cas9 systems, and the combined antitumor activity of ataxia telangiectasia and Rad3-related protein kinase (ATR) inhibitor and trabectedin in sarcoma cell lines using in vitro a cell viability assay and in vivo xenograft models. Results: SLFN11-knockdown cell lines had a lower sensitivity to trabectedin, compared to parental cells. ATR inhibitor enhanced the antitumor activity of trabectedin in SLFN11-knockdown cells and in a SLFN11-knockout xenograft model. Conclusion: SLFN11 expression might be a key factor in the antitumor activity of trabectedin.
掲載誌名
Anticancer Research
ISSN
02507005
17917530
cat書誌ID
AA10625860
AA12440673
出版者
The International Institute of Anticancer Research
39
7
開始ページ
3553
終了ページ
3563
発行日
2019-07
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
生物資源系